Publications by authors named "Satoshi Hashigaki"

Claim this Profile
A
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
Norikazu Masuda, Hirofumi Mukai, Kenichi Inoue, Yoshiaki Rai, Shinji Ohno, Satoshi Hashigaki

Breast Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study.
Masato Takahashi, Norikazu Masuda, Reiki Nishimura, Kenichi Inoue, Shinji Ohno, Satoshi Hashigaki

Cancer Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Norikazu Masuda, Hirofumi Mukai, Kenichi Inoue, Yoshiaki Rai, Shinji Ohno, Satoshi Hashigaki

Breast Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Norikazu Masuda, Hirofumi Mukai, Kenichi Inoue, Yoshiaki Rai, Shinji Ohno, Satoshi Hashigaki

Breast Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings.
Naomi Ueno, Shigeo Banno, Yutaka Endo, Motoko Tamura, Katsuko Sugaya, Satoshi Hashigaki

Jpn J Clin Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
Tetsuhide Ito, Takuji Okusaka, Toshirou Nishida, Kenji Yamao, Hisato Igarashi, Satoshi Hashigaki

Invest New Drugs· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
Tetsuhide Ito, Masayuki Tori, Satoshi Hashigaki, Nobuyuki Kimura, Kazuo Sato

Jpn J Clin Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients.
Norikazu Masuda, Kenichi Inoue, Rikiya Nakamura, Yoshiaki Rai, Hirofumi Mukai, Satoshi Hashigaki

Int J Clin Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.
Hirofumi Mukai, Chikako Shimizu, Norikazu Masuda, Shoichiro Ohtani, Shinji Ohno, Satoshi Hashigaki

Int J Clin Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.
Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J Solomon, Satoshi Hashigaki

Cancer Res Treat· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.
Norikazu Masuda, Reiki Nishimura, Masato Takahashi, Kenichi Inoue, Shinji Ohno, Satoshi Hashigaki

Cancer Sci· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients.
Kenji Tamura, Hirofumi Mukai, Yoichi Naito, Kan Yonemori, Makoto Kodaira, Satoshi Hashigaki

Cancer Sci· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly.
Akira Shimatsu, Masahito Nagashima, Satoshi Hashigaki, Nobuhiko Ohki, Kazuo Chihara

Endocr J· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How Should a Globalized CTD Be Created? An Introduction to the Japanese 3-Layer Approach.
Katsumi Yoshida, Naoto Awaji, Kazumasa Takenouchi, Yuko Asahara, Satoshi Hashigaki

Ther Innov Regul Sci· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.
Narikazu Boku, Kei Muro, Nozomu Machida, Satoshi Hashigaki, Nobuyuki Kimura

Invest New Drugs· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
Tetsuhide Ito, Takuji Okusaka, Toshirou Nishida, Kenji Yamao, Hisato Igarashi, Satoshi Hashigaki

Invest New Drugs· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Hiroji Iwata, Norikazu Masuda, Shinji Ohno, Yoshiaki Rai, Yasuyuki Sato, Satoshi Hashigaki

Breast Cancer Res Treat· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Yasushi Tsuji, Taroh Satoh, Akihito Tsuji, Kei Muro, Motoki Yoshida, Satoshi Hashigaki

Cancer Sci· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.
Takayuki Yoshino, Kentaro Yamazaki, Tetsuya Hamaguchi, Yasuhiro Shimada, Ken Kato, Satoshi Hashigaki

Anticancer Res· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis